937273-31-9

Usage

Molecular structure

The compound consists of an allyloxy methyl group, a 2-chloroethoxy group, and a nitrobenzene ring.

Physical properties

It is a yellow, crystalline solid.

Uses

It is commonly used in organic synthesis, pharmaceuticals, and as a building block for other chemicals.

Reactivity

The presence of the allyloxy and chloroethoxy groups make it suitable for use as a reactive intermediate in various chemical reactions.

Chemical modification potential

The nitrobenzene ring provides aromatic character and potential for further chemical modification.

Industrial and research applications

2-((allyloxy)Methyl)-1-(2-chloroethoxy)-4-nitrobenzene may have various industrial and research applications due to its versatile reactivity and potential for use in the development of new processes and materials.

Upstream product

• 937273-30-8 [2-(2-chloroethoxy)-5-nitrophenyl]methanol 
• 106-95-6 allyl bromide 
• 97-51-8 5-Nitrosalicylaldehyde 
• 110837-53-1 2-(2-chloroethoxy)-5-nitrobenzaldehyde 
• 2460-58-4 2-hydroxy-4-nitrobenzaldehyde 

Downstream Products

• 937273-32-0 1-(2-{4-nitro-2-[(prop-2-en-1-yloxy)methyl]phenoxy}ethyl)pyrrolidine 
• 1083089-86-4 [4-(3-allyloxymethyl-piperidin-1-yl)-pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine 
• 1364124-02-6 [4-(1-allyl-1H-indol-6-yl)-5-methylpyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine 
• 1083182-45-9 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(2-fluoropyridin-4-yl)-5-methylpyrimidin-2-yl]amine 
• 1083182-44-8 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(2-fluoropyridin-4-yl)pyrimidin-2-yl]amine 
• 1364124-00-4 [4-(5-allyloxymethylpyridin-3-yl)pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine 
• 1364123-99-8 [4-(4-allyloxymethylfuran-2-yl)pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine 
• 937273-38-6 [4-(5-allyloxymethylfuran-2-yl)pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine 
• 937273-46-6 [4-(5-allyloxymethylfuran-3-yl)pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine 
• 937273-42-2 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(5-allyloxymethylthiophen-3-yl)pyrimidin-2-yl]amine 
• 937273-37-5 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(5-allyloxymethylthiophen-2-yl)pyrimidin-2-yl]amine 
• 1027635-72-8 [4-(1-allyl-1H-indol-6-yl)pyrimidin-2-yl]-[3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]amine 
• 1083182-47-1 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(2-but-3-enyloxypyridin-4-yl)-5-methylpyrimidin-2-yl]amine 
• 1083182-46-0 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(2-but-3-enyloxypyridin-4-yl)pyrimidin-2-yl]amine 

Relevant academic research and scientific papers

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is 50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK-HDAC pathway inhibiton achieved with a single molecule.

Discovery of the macrocycle (9 E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25- trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9, 14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of Janus kinase 2/Fms-liketyrosine kinase-3 (J

Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (

Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7, 26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27) ,16,21,23-decaene (SB1518), a potent Janus Kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma

Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2 V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2 WT and JAK2V617F, respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.

PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES

The present invention relates to pyridyl substituted pyrimidine compounds that are useful as agents for the treatment of kinase related disorders such as proliferative disorders. More particularly, the present invention relates to oxygen linked and pyridy

INDOLE SUSTITUTED PYRIMIDINES AND USE THEREOF IN THE TREATMENT OF CANCER

The present invention relates to pyrimidine compounds of formula (I) that are useful as anti proliferative agents. More particularly, the present invention relates to indole substituted pyrimidine compounds, methods for their preparation, pharmaceutical c

HETEROCYCLOALKYL SUBSTIITUTED PYRIMIDINE DERIVATIVES

The present invention relates to pyrimidine compounds that are useful as agents for the treatment of kinase related disorders such as proliferative disorders. More particularly, the present invention relates to heterocycloalkyl substituted pyrimidine comp

OXYGEN LINKED PYRIMIDINE DERIVATIVES

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.